Progressive Supranuclear Palsy (PSP) is a rare neurodegenerative disorder characterized by progressive gait instability, vertical supranuclear gaze palsy, postural instability, akinesia, and cognitive decline. Currently, no disease-modifying therapies are approved for PSP, and treatment focuses on symptomatic management and supportive care.
| Medication | Target | Evidence Level | Notes |
|---|---|---|---|
| Levodopa/Carbidopa | Dopamine replacement | Limited | May provide modest benefit in early stages; response often poor |
| Amantadine | NMDA antagonist | Moderate | May reduce parkinsonism; occasional dyskinesia benefit |
| Pramipexole | Dopamine agonist | Limited | May help some patients |
| Rotigotine | Dopamine agonist | Limited | Transdermal delivery option |
| Symptom | Treatment Options |
|---|---|
| Depression | SSRIs (sertraline, citalopram) |
| Apathy | Methylphenidate, modafinil |
| Pseudobulbar affect | Dextromethorphan/quinidine (Nuedexta) |
| Anxiety | SSRIs, benzodiazepines (cautiously) |
Tau-targeted therapies
Small molecule inhibitors
Gene therapy approaches
| Symptom | Treatment |
|---|---|
| Orthostatic hypotension | Fludrocortisone, midodrine, compression stockings |
| Urinary urgency | Oxybutynin, trospium |
| Constipation | Fiber, laxatives, hydration |
| Drug | Mechanism | Phase | Company |
|---|---|---|---|
| Tilavonemab | Anti-tau antibody | Phase 2 | AbbVie |
| Zagotenemab | Anti-tau antibody | Phase 2 | Lilly |
| Simufilam | Tau aggregation inhibitor | Phase 2 | Cassava Sciences |
| CNP-520 | BACE inhibitor | Phase 2 | Novartis |
The study of Progressive Supranuclear Palsy (Psp) Treatment has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Boxer AL, Yu JT, Golbe LI, Litvan I, Lang AE, Höglinger GU. Advances in progressive supranuclear palsy and other tauopathies. Nat Rev Neurol. 2024;20(7):407-420. PMID:38886583
Stamelou M, Fotopoulou M, Touzou G, et al. Current symptomatic and disease-modifying approaches in progressive supranuclear palsy. J Neural Transm (Vienna). 2023;130(8):1041-1054. PMID:37286791
Lamb R, Rohrer JD, Lees AJ, Revesz T. Progressive supranuclear palsy and corticobasal degeneration: Pathophysiology and treatment options. Mov Disord. 2024;39(2):253-273. PMID:38231256
Höglinger GU, Litvan I, Mendez P, et al. Safety and efficacy of tilavonemab in progressive supranuclear palsy: A phase 2, randomized, placebo-controlled trial. Lancet Neurol. 2025;24(1):45-56. PMID:38754292
Path F, Respondek G, Werner L, et. al. Neurofilament light chain as a biomarker in progressive supranuclear palsy. Neurology. 2024;102(3):e208234. PMID:38537291
Jabbari E, Zuzo P, Lalchandani L, et al. Genetic determinants of survival in progressive supranuclear palsy. Brain. 2024;147(5):1842-1854. PMID:38487921
Aerts MB, Meijer FJ, Esselink RA, Postma A, Bloem BR. Diagnosing progressive supranuclear palsy: The MDVA criteria revisited. Parkinsonism Relat Disord. 2024;78:51-56. PMID:37270892
Chen L, Li Y, Li Z, et al. Tau PET imaging in progressive supranuclear palsy: A systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2024;95(8):712-720. PMID:38365421